# Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

> **NCT00074490** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 442 (actual)

## Conditions studied

- Lymphoma
- Leukemia
- Myeloproliferative Disorders
- Multiple Myleoma
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Fludarabine
- **DRUG:** Etoposide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Peripheral blood stem cell (PBSC) transplantation
- **GENETIC:** T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
- **DRUG:** Prednisone
- **PROCEDURE:** Allogeneic hematopoietic stem cell transplant (HSCT)
- **DRUG:** Filgrastim
- **GENETIC:** T-Rapa cell Donor Lymphocyte Infusion (DLI)

## Key facts

- **NCT ID:** NCT00074490
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-01-01
- **Primary completion:** 2017-07-20
- **Final completion:** 2017-08-16
- **Target enrollment:** 442 (ACTUAL)
- **Why stopped:** Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2
- **Last updated:** 2018-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074490, "Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00074490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*